# Insilico Medicine

the Pharma.AI / Chemistry42 platform; its generative-AI-discovered TNIK inhibitor ISM001-055 (rentosertib) for idiopathic pulmonary fibrosis reported positive Phase IIa topline results (published in Nature Medicine) and is advancing toward pivotal trials — a flagship AI-designed asset.

Source: https://en.bioecon.ru/companies/insilico-medicine/
Updated: 2026-06-30

- Country: China

## Technologies

- [AI drug design & AlphaFold applications](https://en.bioecon.ru/technology/ai-drug-design-alphafold-applications/)